Cole L B, Kilpatrick J M, Chu N, Babu Y S
BioCryst Pharmaceuticals, Inc., 2190 Parkway Lake Drive, Birmingham, AL 35244-2812, USA.
Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):711-7. doi: 10.1107/s0907444997010457.
Factor D (D) is a serine protease essential in the activation of the alternative complement pathway. Only a few of the common serine protease inhibitors inhibit D, binding covalently to the serine hydroxyl of the catalytic triad. 3,4-Dichloroisocoumarin (DCI) is a mechanism-based inhibitor which inhibits most serine proteases and many esterases, including D. The structure of the enzyme:inhibitor covalent adduct of D with DCI, DCI:D, to a resolution of 1.8 A is described, which represents the first structural analysis of D with a mechanism-based inhibitor. The side chain of the ring-opened DCI moiety of the protein adduct undergoes chemical modification in the buffered solution, resulting in the formation of an alpha-hydroxy acid moiety through the nucleophilic substitution of both Cl atoms. The inhibited enzyme is similar in overall structure to the native enzyme, as well as to a variety of isocoumarin-inhibited trypsin and porcine pancreatic elastase (PPE) structures, yet notable differences are observed in the active site and binding mode of these small-molecule inhibitors. One region of the active site (residues 189-195) is relatively conserved between factor D, trypsin, and elastase with respect to amino-acid sequence and to conformation. Another region (residues 214-220) reflects the amino-acid substitutions and conformational flexibility between these enzymes. The carbonyl O atom of the DCI moiety was found to be oriented away from the oxyanion hole, which greatly contributes to the stability of the DCI:D adduct. The comparisons of the active sites between native factor D, DCI-inhibited factor D, and various inhibited trypsin and elastase (PPE) molecules are providing the chemical bases directing our design of novel, small-molecule pharmaceutical agents capable of modulating the alternative complement pathway.
D因子(D)是替代补体途径激活过程中必需的一种丝氨酸蛋白酶。只有少数常见的丝氨酸蛋白酶抑制剂能抑制D因子,它们与催化三联体的丝氨酸羟基共价结合。3,4-二氯异香豆素(DCI)是一种基于机制的抑制剂,可抑制大多数丝氨酸蛋白酶和许多酯酶,包括D因子。本文描述了D因子与DCI形成的酶-抑制剂共价加合物(DCI:D)的结构,分辨率为1.8 Å,这是对D因子与基于机制的抑制剂的首次结构分析。蛋白质加合物中开环的DCI部分的侧链在缓冲溶液中会发生化学修饰,通过两个Cl原子的亲核取代形成α-羟基酸部分。被抑制的酶在整体结构上与天然酶相似,也与多种异香豆素抑制的胰蛋白酶和猪胰弹性蛋白酶(PPE)结构相似,但在这些小分子抑制剂的活性位点和结合模式上观察到显著差异。活性位点的一个区域(第189 - 195位残基)在D因子、胰蛋白酶和弹性蛋白酶之间,在氨基酸序列和构象方面相对保守。另一个区域(第214 - 220位残基)反映了这些酶之间的氨基酸取代和构象灵活性。发现DCI部分的羰基O原子远离氧阴离子孔,这对DCI:D加合物的稳定性有很大贡献。对天然D因子、DCI抑制的D因子以及各种被抑制的胰蛋白酶和弹性蛋白酶(PPE)分子的活性位点进行比较,为我们设计能够调节替代补体途径的新型小分子药物提供了化学基础。